CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0001402: Hepatocellular carcinomaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug287 Colchicine 1 MG Oral Tablet Wiki 1.00
drug1351 nasopharyngeal Covid 19 RT-PCR Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D006528 Carcinoma, Hepatocellular NIH 1.00
D002277 Carcinoma NIH 0.71

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0030731 Carcinoma HPO 0.71

There is one clinical trial.

Clinical Trials

1 Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort

Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic

NCT04367805 Hepatocellular Carcinoma COVID-19 Diagnostic Test: nasopharyngeal Covid 19 RT-PCR
MeSH:Carcinoma Carcinoma, Hepatocellular
HPO:Carcinoma Hepatocellular carcinoma

Primary Outcomes

Description: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Measure: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Time: 6 months

HPO Nodes